The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation

Overview

Journal J Cardiovasc Pharmacol

Date 2020 Nov 9

PMID 33165133

Citations 11

Authors

Charikleia Kalliora

Konstantinos Drosatos

Affiliations

Soon will be listed here.

Abstract

The most common complications in patients with type-2 diabetes are hyperglycemia and hyperlipidemia that can lead to cardiovascular disease. Alleviation of these complications constitutes the major therapeutic approach for the treatment of diabetes mellitus. Agonists of peroxisome proliferator-activated receptor (PPAR) alpha and PPARγ are used for the treatment of hyperlipidemia and hyperglycemia, respectively. PPARs belong to the nuclear receptors superfamily and regulate fatty acid metabolism. PPARα ligands, such as fibrates, reduce circulating triglyceride levels, and PPARγ agonists, such as thiazolidinediones, improve insulin sensitivity. Dual-PPARα/γ agonists (glitazars) were developed to combine the beneficial effects of PPARα and PPARγ agonism. Although they improved metabolic parameters, they paradoxically aggravated congestive heart failure in patients with type-2 diabetes via mechanisms that remain elusive. Many of the glitazars, such as muraglitazar, tesaglitazar, and aleglitazar, were abandoned in phase-III clinical trials. The objective of this review article pertains to the understanding of how combined PPARα and PPARγ activation, which successfully targets the major complications of diabetes, causes cardiac dysfunction. Furthermore, it aims to suggest interventions that will maintain the beneficial effects of dual PPARα/γ agonism and alleviate adverse cardiac outcomes in diabetes.

Citing Articles

The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.

Kounatidis D, Vallianou N, Rebelos E, Kouveletsou M, Kontrafouri P, Eleftheriadou I Curr Obes Rep. 2025; 14(1):19.

PMID: 39934485 DOI: 10.1007/s13679-025-00612-4.

Triterpenoids from Chios Mastiha Resin Against MASLD-A Molecular Docking Survey.

Milosevic N, Milanovic M, Medic Stojanoska M, Tipmanee V, Smyrnioudis I, Dedoussis G Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852166 PMC: 11763944. DOI: 10.3390/cimb47010051.

Cardioprotection strategies for anthracycline cardiotoxicity.

Moreno-Arciniegas A, Cadiz L, Galan-Arriola C, Clemente-Moragon A, Ibanez B Basic Res Cardiol. 2024; 120(1):71-90.

PMID: 39249555 PMC: 11790697. DOI: 10.1007/s00395-024-01078-6.

Novel Therapeutics for Type 2 Diabetes Mellitus-A Look at the Past Decade and a Glimpse into the Future.

Chee Y, Dalan R Biomedicines. 2024; 12(7).

PMID: 39061960 PMC: 11274090. DOI: 10.3390/biomedicines12071386.

PPAR agonists as add-on treatment with metformin in management of type 2 diabetes: a systematic review and meta-analysis.

Alnuaimi S, Reljic T, Abdulla F, Memon H, Al-Ali S, Smith T Sci Rep. 2024; 14(1):8809.

PMID: 38627464 PMC: 11021491. DOI: 10.1038/s41598-024-59390-z.

References

Zhang B, Berger J, Hu E, Szalkowski D, Spiegelman B, Moller D . Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol. 1996; 10(11):1457-66. DOI: 10.1210/mend.10.11.8923470. View

Horscroft J, OBrien K, Clark A, Lindsay R, Steel A, Procter N . Inorganic nitrate, hypoxia, and the regulation of cardiac mitochondrial respiration-probing the role of PPARα. FASEB J. 2019; 33(6):7563-7577. PMC: 6529343. DOI: 10.1096/fj.201900067R. View

Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A . The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109(1):121-30. PMC: 150824. DOI: 10.1172/JCI14080. View

Cai G, Liu J, Wang M, Su L, Cai M, Huang K . Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension. Exp Biol Med (Maywood). 2019; 244(3):252-261. PMC: 6425103. DOI: 10.1177/1535370219828692. View

Aoi W, Naito Y, Mizushima K, Takanami Y, Kawai Y, Ichikawa H . The microRNA miR-696 regulates PGC-1{alpha} in mouse skeletal muscle in response to physical activity. Am J Physiol Endocrinol Metab. 2010; 298(4):E799-806. DOI: 10.1152/ajpendo.00448.2009. View

Harrity T, Farrelly D, Tieman A, Chu C, Kunselman L, Gu L . Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes. 2005; 55(1):240-8. View

Razeghi P, Young M, Abbasi S, Taegtmeyer H . Hypoxia in vivo decreases peroxisome proliferator-activated receptor alpha-regulated gene expression in rat heart. Biochem Biophys Res Commun. 2001; 287(1):5-10. DOI: 10.1006/bbrc.2001.5541. View

Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O . Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005; 1(4):259-71. DOI: 10.1016/j.cmet.2005.03.002. View

Oster R, Tishinsky J, Yuan Z, Robinson L . Docosahexaenoic acid increases cellular adiponectin mRNA and secreted adiponectin protein, as well as PPARγ mRNA, in 3T3-L1 adipocytes. Appl Physiol Nutr Metab. 2010; 35(6):783-9. DOI: 10.1139/H10-076. View

10.

Nolan C, Ruderman N, Kahn S, Pedersen O, Prentki M . Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes. 2015; 64(3):673-86. PMC: 4338588. DOI: 10.2337/db14-0694. View

11.

Mahaffey K, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J . Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013; 166(2):240-249.e1. DOI: 10.1016/j.ahj.2013.05.004. View

12.

Escher P, Braissant O, Michalik L, Wahli W, Desvergne B . Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology. 2001; 142(10):4195-202. DOI: 10.1210/endo.142.10.8458. View

13.

LEHMAN J, Barger P, Kovacs A, Saffitz J, Medeiros D, Kelly D . Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000; 106(7):847-56. PMC: 517815. DOI: 10.1172/JCI10268. View

14.

Sun L, Wang N, Ban T, Sun Y, Han Y, Sun L . MicroRNA-23a mediates mitochondrial compromise in estrogen deficiency-induced concentric remodeling via targeting PGC-1α. J Mol Cell Cardiol. 2014; 75:1-11. DOI: 10.1016/j.yjmcc.2014.06.012. View

15.

Loichot C, Jesel L, Tesse A, Tabernero A, Schoonjans K, Roul G . Deletion of peroxisome proliferator-activated receptor-alpha induces an alteration of cardiac functions. Am J Physiol Heart Circ Physiol. 2006; 291(1):H161-6. DOI: 10.1152/ajpheart.01065.2004. View

16.

Caglayan E, Stauber B, Collins A, Lyon C, Yin F, Liu J . Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes. 2008; 57(9):2470-9. PMC: 2518499. DOI: 10.2337/db07-0924. View

17.

Nakamura M, Liu T, Husain S, Zhai P, Warren J, Hsu C . Glycogen Synthase Kinase-3α Promotes Fatty Acid Uptake and Lipotoxic Cardiomyopathy. Cell Metab. 2019; 29(5):1119-1134.e12. PMC: 6677269. DOI: 10.1016/j.cmet.2019.01.005. View

18.

Huss J, Torra I, Staels B, Giguere V, Kelly D . Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol. 2004; 24(20):9079-91. PMC: 517878. DOI: 10.1128/MCB.24.20.9079-9091.2004. View

19.

Hata K, Nishimura R, Ikeda F, Yamashita K, Matsubara T, Nokubi T . Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. Mol Biol Cell. 2003; 14(2):545-55. PMC: 149991. DOI: 10.1091/mbc.e02-06-0356. View

20.

Sen Banerjee S, Feinberg M, Watanabe M, Gray S, Haspel R, Denkinger D . The Krüppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis. J Biol Chem. 2002; 278(4):2581-4. DOI: 10.1074/jbc.M210859200. View